BTLA and cancer: Phosphatase recruitment by Btla or the checkpoint protein programmed cell death protein-1 (PD-1, Pdcd1) inhibits T cell activation, providing evidence for targeting both receptors together in cancer immunotherapy (Celis-Gutierrez et al., 2019).